Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma
Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.
Diagnosis & Disease Information
IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom’s Macroglobulinemia
Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.
Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.
Encorafenib Plus Binimetinib for Metastatic Melanoma
Victor Sandor, MD, discusses the treatment combination at the ASCO 2018 meeting in Chicago.
Metronomic Maintenance Therapy Significantly Improves Overall Survival in Rhabdomyosarcoma
Researchers sought to determine if maintenance treatment with metronomic chemotherapy would improve survival outcomes in rhabdomyosarcoma.
Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26
The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.
Latest Innovations in Value-Based Specialty Care
Charles Saunders, MD, speaks at the American Society of Clinical Oncology (ASCO) 2018 meeting in Chicago.
Innovations in Engaging T-cells
Venkateshwar Reddy, MD, discusses research at the ASCO 2018 meeting.
Investigational Studies on Lenvatinib, Pembrolizumab
Josh Kremer, MD, discusses the latest research at the ASCO 2018 meeting.
Cemiplimab for Cutaneous Squamous Cell Carcinoma
Danny Rischin, MBBS, FRACP, MD, speaks at the American Society of Clinical Oncology (ASCO) 2018 meeting.
- Loading...
Loading...
Loading... 
Loading...